Source: Business Wire

Harpoon: Merck Completes Acquisition of Harpoon Therapeutics, Inc.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon's common stock will no longer be publicly traded or listed on the Nasdaq Stock Market. "We continue to augment and diversify our oncology pipeline with innovative approaches to help people with cancer worldwide," said Dr. Dean Y. Li, pr

Read full article »
Annual Revenue
$25-100M
Employees
25-100
CEO Avatar

CEO

- -

CEO Approval Rating

- -/100

Read more